DNA Bridges, Inc. Bridging Science and Technology


	DNA Bridges^®, - Bridging Science and Products Expert consulting and professional services in the biotechnology, pharmaceutical and diagnostic industries. Strategic solutions based on 30 years of industry experience.

Home

Services

Our Team

Hot Topics/News

Philosophy

Testimonials

Site Map

home hot topics/news 2009

ARCHIVES 2009 | 2008 | 2007 |2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000

December 10, 2009
Azaya Therapeutics Receives FDA Authorization to Start Phase I Cancer Trial
More
November 11-13, 2009
Texas Life Science Conference 2009
The Brown Foundation Institute of Molecular Medicine
Houston, Texas
More
November 2-4, 2009
BIO-Europe 2009
Messe Wien Exhibition & Congress Center
Vienna, Austria
More
October 12-16, 2009
BioProcess International Conference and Exhibition
Raleigh Convention Center
Raleigh-Durham, North Carolina
More
October 5, 2009
Depomed, Inc. Announces Positive Top-Line Results from Phase 3 Clinical Trial of DM-1796 in Postherpetic Neuralgia
Menlo Park, Calif
More
September 22, 2009
Selexis and Neogenix Oncology enter into research services agreement
Geneva, Switzerland, and Great Neck, New York
More
September 18, 2009
Wyeth and Ambrx Form Multi-target Alliance to Leverage Recent Ambrx Biologics Platform Advances
Collegeville, PA and San Diego, CA
More
September 17, 2009
to-BBB technology will be used by MedImmune to evaluate brain drug delivery mechanism
Leiden, The Netherlands
More
August 31, 2009
Selexis and NKT Therapeutics enter into research services agreement
Geneva, Switzerland
More
August 10, 2009
Depomed Reports Encouraging Results of its Phase I Trial for DM-1992 Program in Parkinson's Disease
Menlo Park, Calif
More
August 6, 2009
to-BBB climbs up the international CNS drug delivery ranking
Leiden, The Netherlands
More
May 19, 2009
Personalized Medicine Can Increase Revenues
By Cammie Edwards, Ph.D., DNA Bridges, Inc.
Featured in Bio Show Daily, Tuesday, May 19, 2009. Page 33.
More
May 19, 2009
Cell Therapy is Alive and Well
By Cori Gorman, Ph.D., MBA, DNA Bridges, Inc.
Featured in Bio Show Daily, Tuesday, May 19, 2009. Page 22
More
May 12, 2009
U.S. Army funds TNO, and to-BBB to investigate protecting soldier’s brains from nerve agents
More
May 8, 2009
Annual Sigma Xi Meeting
Lecture: The Thrill of Victory the Agony of Defeat, the Trials of Developing a New Class of Therapeutics: From Gene to Cell Therapy, A Case Study
More
May 5, 2009
Viroblock SA Reports a 99% Boost of Efficacy of Facemasks against H5N1
More
April 14, 2009
Promising Test for Dendreon's Prostate Cancer Drug
More
April 11, 2009
FDA Approves Treatment of Head Lice - Target Health Was THE CRO
More
April 7, 2009
Dr. Cori Gorman Completes ISS Certification in Corporate Directors Enterprise 2009 Program
More
April 7, 2009
Editorial: Enabling High Throughput Drug Development
More
April 2, 2009
Editorial: Personalized Medicine Can Increase Revenues
More
March 31, 2009
Selexis launches Biosimilar Cell Line Development Program
More
March 31, 2009
Positive Results of Preclinical Studies in Antiviral Nasal Spray
More
March 24, 2009
Editorial: Cell Therapy Market
Cori Gorman, PhD, MBA
Read Article

55 New Montgomery Street, Suite 605
San Francisco, CA 94105
TEL 415 362-0442
FAX 415 536-2871

5 Bisbee Court, Suite 109-225
Santa Fe, NM 87508-1419
TEL 505-473-2703
FAX 505-474-9032